Skip to main content

Table 3 Serum levels of resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) in Kawasaki disease (KD) with or without coronary artery lesions (CALs)

From: Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease

Characteristic KD with CALs
(n= 9)
KD without CALs
(n= 31)
P
Boys/girls, number 4/5 18/13 0.000
Age, months 27.1 (20.7) 22.1 (15.6) 0.001
Resistin, 102 ng/ml Acute stage 0.46 (0.24) 0.36 (0.26) 0.268
  Afebrile stage 0.31 (0.20) 0.22 (0.22) * 0.266
  Subacute stage 0.15 (0.08)** 0.13 (0.08) ** 0.663
S100A12, 102 ng/ml Acute stage 5.09 (2.78) 5.40 (3.42) 0.804
  Afebrile stage 4.22 (3.29) 4.02 (3.63) 0.883
  Subacute stage 2.52 (3.16) 2.65 (2.53)** 0.899
sRAGE, 102 pg/ml Acute stage 2.97(1.99) 3.01 (1.92) 0.959
  Afebrile stage 5.93 (3.59)* 5.70 (2.64)** 0.833
  Subacute stage 7.06 (3.88)* 6.77 (2.86)** 0.802
  1. Results are mean (SD) unless stated otherwise. *P < 0.05, **P < 0.01 compared with acute stage; P < 0.05 compared with group afebrile stage.